

CURRENT REPORT 31/2023

June 14th, 2023

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") hereby announces that the following shareholders controlled at least 5% of the vote at the General Shareholders Meeting of the Company ("General Meeting") convened on June 14th, 2023:

1. Paweł Przewięźlikowski: 4,065,036 shares of the Company, which entitled to exercise 7,565,036 votes, which constituted respectively 29.75% of shares at the GM and 42.70% of votes at the GM and 27.84% in the total number of votes;

2. Bogusław Sieczkowski: 825,348 shares of the Company, which entitled to exercise 1,375,348 votes, which constituted respectively 6.04% of shares at the GM and 7.76% of votes at the GM and 5.06% in the total number of votes;

3. Nationale-Nederlanden Otwarty Fundusz Emerytalny: 1,900,000 shares in the Company, which entitled to exercise 1,900,000 votes, which constituted 13.90% of shares at the GM and 10.72% of votes at the GM and 6.99% of the total number of votes, respectively;

4. Augebit FIZ: 1,279,738 shares of the Company, which entitled to exercise 1,279,738 votes, which constituted respectively 9.36% of shares at the GM and 7.22% of votes at the GM and 4.71% in the total number of votes;

5. Towarzystwo Funduszy Inwestycyjnych Allianz Polska S.A.: 1,910,236 shares in the Company, which entitled to exercise 1,910,236 votes, representing 13.98% of shares at the GM 10.78% of votes at the GM and 7.03% of the total number of votes, respectively;

6. Allianz Polska Otwarty Fundusz Emerytalny: 2,132,000 shares of the Company, which entitled to exercise 2,132,000 votes, which constituted respectively 15.60% of shares at the GM and 12.03% of votes at the GM and 7.85% in the total number of votes.

7. Otwarty Fundusz Emerytalny PZU "Złota Jesień": 1,028,913 shares of the Company, which entitled to exercise 1,028,913 votes, which constituted respectively 7.53% of shares at the GM and 5.81% of votes at the GM and 3.79% in the total number of votes.

According to the attendance list, shareholders holding 13,666,247 shares entitling them to exercise 17,716,247 votes were represented at the GM.

The total number of shares in the Company is 23,120,148, entitling to 27,170,148 votes.

Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 56.1.2 of the Act on Offerings

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board